Epigenomics AG: Release of a Voting Rights Notification
February 20, 2008 08:12 ET
|
Epigenomics AG
BERLIN, Germany, Feb. 20, 2008 (PRIME NEWSWIRE) -- Voting Rights Notification (section 21 para. 1 WpHG) in accordance with section 26, para. 1 WpHG (German Securities Trading Act):
On February 19,...
Epigenomics Licenses Septin 9 Colorectal Cancer Biomarker to Quest Diagnostics
February 19, 2008 12:35 ET
|
Epigenomics AG
BERLIN, Feb. 19, 2008 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (Other OTC:EPGNF), a cancer molecular diagnostics company, today announced that it signed a non-exclusive licensing agreement...
Epigenomics AG: Ad hoc (#15 WpHG): Epigenomics Licenses Septin 9 Colorectal Cancer Biomarker to Quest Diagnostics
February 19, 2008 12:28 ET
|
Epigenomics AG
BERLIN, Feb. 19, 2008 (PRIME NEWSWIRE) -- Epigenomics AG (Other OTC:EPGNF) (Frankfurt:ECX) today announced that it signed a non-exclusive licensing agreement for its proprietary DNA methylation...
Epigenomics AG Reports Third Quarter 2007 Results
October 31, 2007 03:42 ET
|
Epigenomics AG
Key Figures (in EUR thousand)
* Revenue: 466 in Q3 2007, down by 61% (Q3 2006: 1,203)
* EBIT: -3,229 in Q3 2007, improved by 15% (Q3 2006: -3,790)
* Net loss: -3,139 in Q3 2007, improved...
Epigenomics AG Forms Medical Advisory Board For Colorectal Cancer Screening
October 10, 2007 03:12 ET
|
Epigenomics AG
BERLIN and SEATTLE, Oct. 10, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (ISIN:DE000A0BVT96) today announced the formation of its Colorectal Cancer Medical Advisory board and the...
Epigenomics AG: Key Patents For Cancer Testing Granted
October 04, 2007 03:13 ET
|
Epigenomics AG
BERLIN and SEATTLE, Oct. 4, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (ISIN: DE000A0BVT96) today announced that key patents covering Epigenomics' core technology HeavyMethyl(r) for the...
Ad hoc: Epigenomics AG: Ad Hoc (Section 15 WpHG): Epigenomics AG Announces Strategic In Vitro Diagnostics Partnership With Abbott Molecular
September 26, 2007 02:24 ET
|
Epigenomics AG
Collaboration Focuses On Development and Global Commercialization of
a Molecular Diagnostic Test for the Early Detection of Colorectal
Cancer
* Abbott obtains non-exclusive worldwide rights to...
Epigenomics AG Updates on Progress in Its Prostate Cancer Test Development
September 18, 2007 05:33 ET
|
Epigenomics AG
BERLIN and SEATTLE, Sept. 18, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), a molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic tests...
Epigenomics AG Reports First Half 2007 Results
August 02, 2007 02:39 ET
|
Epigenomics AG
Key Figures (in EUR thousand)
* Revenues: 1,343 in H1 2007; increased by 23% (H1 2006: 1,096)
* EBIT: -6,949 in H1 2007; improved by 18% (H1 2006: -8,431)
* Net loss: -6,699 in H1 2007; reduced...
Epigenomics AG Successfully Optimized Assay Procedure for Cancer Screening Tests
July 03, 2007 02:39 ET
|
Epigenomics AG
-- Technical study met its objectives
-- Considerable improvements in simplicity, processing time, costs, and
automation potential
-- Epigenomics most advanced program, a colorectal cancer...